Latest Gene therapy Stories
Gene therapy leader to advance its deep pipeline of rare disease programs including its lead Phase 3 product candidate for RPE65-related blindness PHILADELPHIA, May 27, 2014 /PRNewswire/
For the first time researchers have succeeded in altering HIV virus particles so that they can simultaneously, as it were, 'cut and paste' in our genome via biological processes.
SB-728-T-Treated Subject Maintains Control of Viral Load for 45 Weeks Without Anti-Retroviral Drugs RICHMOND, Calif., May 27, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc.
Transparency Market Research added a new report "Global Gene Therapy Market: Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019" to its report store.
In Addition, Toca 511 Clinical Data to be Presented at American Society of Clinical Oncology Annual Meeting SAN DIEGO, May 22, 2014 /PRNewswire/ --
RICHMOND, Calif., May 14, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc.
Gene therapy leader will house business operations and manufacturing in a growing and dynamic biotech hub PHILADELPHIA, May 13, 2014 /PRNewswire/ --
MOUNTAIN VIEW, Calif., May 5, 2014 /PRNewswire/ -- Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., today announced that it has partnered with Vectalys SAS to combine
TARRYTOWN, N.Y. and MENLO PARK, Calif., May 5, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.
New research looking at the success of clinical trials of stem cell therapy shows that trials appear to be more successful in studies where there are more discrepancies in the trial data.
- A member of the swell-mob; a genteelly clad pickpocket. Sometimes mobsman.
More Images (1 images) »